Literature DB >> 12873332

Which antidepressants flick the switch?

Gordon Parker1, Kay Parker.   

Abstract

OBJECTIVE: The Black Dog Institute seeks to address issues of relevance to the clinical management of those with a mood disorder. This overview considers the capacity of antidepressant drugs, and particularly the new classes, to induce manic switching in depressed patients.
METHOD: Relevant literature is reviewed.
RESULTS: It is unclear whether antidepressant drugs from any of the classes induce switching in unipolar depressed patients. In bipolar depressed patients, the broad-spectrum tricyclic and monoamine oxidase inhibitor drugs present a clear risk of switching, the selective serotonin re-uptake inhibitors do not appear (at standard doses) to increase the risk, while the capacity of the dual action (serotonergic and noradrenergic) drugs to induce switching remains unestablished but may be slight.
CONCLUSIONS: As switching induced by narrow action antidepressants does not appear to present a substantive causal risk, clinicians can have confidence in prescribing certain anti-depressants for managing bipolar depression, and without any necessity to first prescribe a mood stabilizer to pre-empt switching.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12873332     DOI: 10.1046/j.1440-1614.2003.01207.x

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  3 in total

1.  Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study.

Authors:  Jay D Amsterdam; Justine Shults
Journal:  Am J Psychiatry       Date:  2010-04-01       Impact factor: 18.112

2.  Comparison of treatment outcome using two definitions of rapid cycling in subjects with bipolar II disorder.

Authors:  Jay D Amsterdam; Lorenzo Lorenzo-Luaces; Robert J DeRubeis
Journal:  Bipolar Disord       Date:  2017-02-03       Impact factor: 6.744

3.  Rapid versus non-rapid cycling bipolar II depression: response to venlafaxine and lithium and hypomanic risk.

Authors:  L Lorenzo-Luaces; J D Amsterdam; I Soeller; R J DeRubeis
Journal:  Acta Psychiatr Scand       Date:  2016-01-24       Impact factor: 6.392

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.